Restless Legs Syndrome Trial, Recruiting NCT07001891 Sponsor: University Hospital, Bordeaux Condition: Restless Legs Syndrome
Back to Restless Legs Syndrome

Restless Legs Syndrome Trial, Recruiting

NCT07001891
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 70 years old
  • If you are a patient (not a healthy volunteer): you have been diagnosed with idiopathic Restless Legs Syndrome (RLS) based on your medical history and meeting 5 specific RLS diagnostic criteria (confirm with trial site)
  • You have a normal result on a standard clinical (physical) examination
  • You are covered by a social security or health insurance scheme
  • You are willing and able to give your free, informed, written consent to take part before the study begins

Who may not be able to join:

  • You have a significant mental health condition or mood disorder (such as severe depression or anxiety)
  • You have a history of, or currently experience, chronic pain unrelated to RLS, epilepsy, a serious head injury, nerve damage (peripheral neuropathy), or diabetes
  • You have significant sleep apnoea, narcolepsy, or your RLS is caused by another medical condition such as kidney failure or pregnancy
  • You have another serious active illness, such as an unstable heart condition or cancer, that could affect your participation or the study results
  • You are unable to have an MRI scan — for example, if you have a pacemaker, metal implants, clips, artificial heart valves, ear implants, metal fragments in your body or eyes, or if you experience claustrophobia or do not wish to have an MRI
  • You are pregnant or currently breastfeeding
  • You are under a legal protection order, deprived of liberty, or otherwise unable to give your own consent to participate (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Imad Marc Antoine GHORAYEB, MD, PhD, University Hospital, Bordeaux

Phone: (0)5.56.79.55.13

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
16 September 2025
Est. completion
1 October 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Functional Connectivity (FC) of the anterior and posterior insular cortex (IC) measured at rest.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov